2-chloro-1-fluoro-3-nitrobenzene

We are 2-chloro-1-fluoro-3-nitrobenzene CAS:21397-07-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   2-chloro-1-fluoro-3-nitrobenzene
CAS.NO:21397-07-9
Synonyms: 2-chloro-1-fluoro-3-nitro-benzene;
EINECS 244-365-6;
2,4-fluoro-3-chloro-nitrobenzene;
2-Chlor-3-fluor-nitrobenzol;
1-chloro-2-fluoro-6-nitro-benzene;
Molecular Formula:C6H3ClFNO2
Molecular Weight: 175.54500
 
Physical and Chemical Properties:
Density: 1.494g/mL at 25 °C(lit.)
Melting point:  /
Boiling point: 243.3ºC at 760 mmHg
Flash point: 101ºC
Index of Refraction:1.554
 
Specification:
Appearance:  liquid
Purity:≥98.0%
 
Packing:25kg/drum
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:   Applications for organic intermediates

2-chloro-1-fluoro-3-nitrobenzene


Related News: High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)acetonitrile CAS:131801-69-9 As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.N- [4- (4-Fluorofenil) -5-formil-6- (1-metiletil) -2-pirimidinil] -N-metil-metanosulfonamida CAS:147118-37-4 We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.703-91-3 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition.

Related Products
Product Name
N-(2-naphthyl)aniline Cas:135-88-6 View Details
Cupric Pyrophosphate View Details
2′-Hydroxy-4′-methylacetophenone Cas:6921-64-8 View Details
2-Chloro-5-fluorobenzoic Acid Cas:2252-50-8 manufacturer Benzoic Acid,2-fluoro-3-nitro- Cas:317-46-4 manufacturer Cesium Hydroxide Cas:35103-79-8 manufacturer Methyl Methoxyacetate manufacturer Nonanoic Acid Cas:112-05-0 manufacturer